Advanced or Metastatic Breast Cancer Clinical Trial
Official title:
A Multicenter, Single-Arm, Open-Label Phase I Clinical Study of Pelareorep With Paclitaxel in Advanced or Metastatic Breast Cancer
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.
This study will enroll patients with advanced or metastatic breast cancer to assess the safety and tolerability of Pelareorep at 1.5×10^10, 3.0×10^10, 4.5×10^10 (TCID50) combined with paclitaxel to fix the MTD or RP2D. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00748553 -
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05187832 -
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT01625286 -
Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT05932667 -
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04742153 -
A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
|
Phase 2 | |
| Not yet recruiting |
NCT06201234 -
Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
|
Phase 2 | |
| Completed |
NCT02154776 -
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
|
Phase 1 | |
| Active, not recruiting |
NCT04494425 -
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT03767335 -
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT06105632 -
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
|
Phase 3 | |
| Completed |
NCT01676753 -
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT01226316 -
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
|
Phase 1 |